<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        204-212-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SORTIVA 25 MG FILM COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LOSARTAN POTASSIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Losartan (SORTIVA) belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels, causing them to tighten. This results in an increase in blood pressure. Losartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax which in turnlowers the blood pressure.</p><p>Losartan slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes. SORTIVA is used:</p><p>&bull; To treat patients with high blood pressure (hypertension) in adults and in children and adolescents 6-18 years of age.</p><p>&bull; To protect the kidney in hypertensive type 2 diabetic patients with laboratory evidence of impaired renal function and proteinuria &ge; 0.5 g per day (a condition in which urine contains an abnormal amount of protein).</p><p>&bull; To treat patients with chronic heart failure when therapy with specific medicines called angiotensin-converting-enzyme inhibitors (ACE inhibitors, medicine used to lower high blood pressure) is not considered suitable by your doctor. If your heart failure has been stabilised with an ACE inhibitor you should not be switched to losartan.</p><p>&bull; In patients with high blood pressure and a thickening of the left ventricle, SORTIVA has been shown to decrease the risk of stroke (&ldquo;LIFE indication&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take SORTIVA &bull; If you are allergic to losartan or to any of the other ingredients of this medicine (listed in section 6). &bull; If you are more than 3 months pregnant. (It is also better to avoid SORTIVA in early pregnancy- see Pregnancy), &bull; If your liver function is severely impaired. &bull; If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. Take special care withSortiva Warnings and precautions Talk to your doctor or pharmacist before taking SORTIVA. You must tell your doctor if you think you are (or might become) pregnant. SORTIVA is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). It is important to tell your doctor before taking SORTIVA: &minus; If you have had a history of angiooedema (swelling of the face, lips, throat, and/or tongue) (see also section 4 &lsquo;Possible side effects&rsquo;). &minus; If you suffer from liver or kidney problems &minus; If you have recently suffered from severe vomiting or diarrhoea leading to an extreme loss of fluid and/or salt in your body. &minus; If you receive diuretics (medicines that increase the amount of water that you pass out through your kidneys) or are under dietary salt restriction leading to an extreme loss of fluid and salt in your body (see section 3 &lsquo;Dosage in special patient groups&rsquo;). &minus; If you are known to have narrowing or blockage of the blood vessels leading to your kidneys or if you have received a kidney transplant recently. &minus; If your liver function is impaired (see sections 2 &quot;Do not take SORTIVA&quot; and 3 &quot;Dosage in special patient groups&quot;). &minus; If you suffer from heart failure with or without renal impairment or concomitant severe life threatening cardiac arrhythmias. Special caution is necessary when you are treated with a &szlig;-blocker concomitantly. &minus; If you have problems with your heart valves or heart muscle (e.g. aortic stenosis or outflow obstruction) &minus; If you suffer from coronary heart disease (caused by a reduced blood flow in the blood vessels of the heart) or from cerebrovascular disease (caused by a reduced blood circulation in the brain). &minus; If you suffer from primary hyperaldosteronism (a syndrome associated with increased secretion of the hormone aldosterone by the adrenal gland, caused by an abnormality within the gland). &minus; If you have a high level of potassium in your blood (hyperkalaemia) &minus; Dual blockage of Renin- Angiotensin System (RAS) with Angiotensin blockers, ACE inhibitors or Aliskiren is associated with increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on Losartan and other agents that affect RAS. &minus; If you are taking any of the following medicines used to treat high blood pressure: &bull; An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. &bull; aliskiren Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading &ldquo;Do not take Sortiva&rdquo;. Children and adolescents SORTIVA has been studied in children. For more information, talk to your doctor. SORTIVA is not recommended for use in children suffering from kidney or liver problems, or children under 6 years old, as limited data are available in these patient groups. Neonates with a history of in utero exposure to Sortiva: If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Other medicines and SORTIVA Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Take particular care if you are taking the following medicines while under treatment with SORTIVA: &minus; Other blood pressure lowering medicines as they may additionally reduce your blood pressure. Blood pressure may also be lowered by one of the following drugs/class of drugs: tricyclic antidepressants, antipsychotics, baclofen, amifostine. &minus; Lithium (used to treat certain types of mental illness) &minus; Medicines which retain potassium or may increase potassium levels (e.g. potassium supplements, potassium-containing salt substitutes or potassium-sparing medicines such as certain diuretics [amiloride, triamterene, spironolactone] or heparin). &minus; Non-steroidal anti-inflammatory drugs such as indometacin, including COX-2-inhibitors (medicines that reduce inflammation, and can be used to help relieve pain) as they may reduce the blood pressure lowering effect of losartan. &minus; Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on Losartan and other agents that affect the RAS. &minus; ACE (angiotensin-converting enzyme) inhibitors (for the treatment of blood pressure, certain heart conditions, kidney disease in patients with diabetes)- Concomitant treatment should be limited to individually defined cases with close monitoring of renal function. Your doctor may need to change your dose and/or to take other precautions: &bull; If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &quot;Do not take Sortiva Tablets&quot; and &quot;Warnings and precautions&quot;. &minus; Do not co-administer Aliskiren with Losartan if you are diabetic. &minus; Avoid use of Aliskiren with Losartan in patients with renal impairment (GFR&lt;60 ml/min). If your kidney function is impaired, the concomitant use of these medicines may lead to a worsening of the kidney function. Lithium containing medicines should not be taken in combination with losartan without close supervision by your doctor. Special precautionary measures (e.g. blood tests) may be appropriate. SORTIVA with food and drink SORTIVA may be taken with or without food. Pregnancy and breast-feeding Pregnancy You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Sortiva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Sortiva. Sortiva is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Breast-Feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Sortiva is not recommended for mothers who are breast feeding, and your doctor may choose another treatment for you if you wish to breast-feed. Especially if your baby is a newborn, or born prematurely. Ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines No studies on the effects on the ability to drive and use machines have been performed. SORTIVA is unlikely to affect your ability to drive or use machines. However, as with many other medicines used to treat high blood pressure, losartan may cause dizziness or drowsiness in some people. If you experience dizziness or drowsiness, you should consult your doctor before attempting such activities.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will decide on the appropriate dose of SORTIVA, depending on your condition and whether you are taking other medicines. It is important to continue taking SORTIVA for as long as your doctor prescribes it in order to maintain smooth control of your blood pressure.</p><p>Adult patients with High Blood Pressure Treatment usually starts with 50 mg losartan (one tablet SORTIVA 50 mg) once a day. The maximal blood pressure lowering effect should be reached 3-6 weeks after beginning treatment. In some patients the dose may later be increased to 100 mg losartan once daily. If you have the impression that the effect of losartan is too strong or too weak, please talk to your doctor or pharmacist.</p><p>Use in children and adolescents</p><p>Children below 6 years of age SORTIVA is not recommended for use in children under 6 years old, as it has not been shown to work in this age group. Use in children and adolescents (6 to 18 years old) The recommended starting dose in patients who weigh between 20 and 50 kg is 0.7 mg of losartan per kg of body weight administered once a day. The doctor may increase the dose if blood pressure is not controlled. Adult patients with high blood pressure and Type 2 diabetes Treatment usually starts with 50 mg losartan (one tablet SORTIVA 50 mg) once a day. The dose may later be increased to 100 mg losartan once daily depending on your blood pressure response. Losartan may be administered with other blood pressure lowering medicines (e.g. diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used medicines that decrease the level of glucose in the blood (e.g. sulfonylureas, glitazones and glucosidase inhibitors).</p><p>Adult Patients with Heart Failure Treatment usually starts with 12.5 mg losartan once a day. Generally, the dose should be increased weekly step-by-step (i.e., 12.5 mg daily, 25 mg daily, 50 mg daily) to the usual maintenance dose of 50 mg once daily, as tolerated by the patient. A maximum dose of 150 mg losartan (for example, three tablets of SORTIVA 50 mg or one tablet each of SORTIVA Forte 100mg and SORTIVA 50 mg) once daily may be used. In the treatment of heart failure, losartan is usually combined with a diuretic (medicine that increases the amount of water that you pass out through your kidneys) and/or digitalis (medicine that helps to make the heart stronger and more efficient) and/or a beta-blocker. Dosage in special patient groups The doctor may advise a lower dose, especially when starting treatment in certain patients such as those treated with diuretics in high doses, in patients with liver impairment, or in patients over the age of 75 years. The use of losartan is not recommended in patients with severe hepatic impairment (see section &quot;Do not take SORTIVA&quot;).</p><p>Administration</p><p>The tablets should be swallowed with a glass of water. You should try to take your daily dose at about the same time each day. It is important that you continue to take SORTIVA until your doctor tells you otherwise. If you take more SORTIVA than you should If you accidentally take too many tablets, contact your doctor immediately. Symptoms of overdose are low blood pressure, increased heartbeat, possibly decreased heartbeat. If you forget to take SORTIVA If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten tablet. If you have any further questions on the use of this medicine, ask your doctor, pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience the following, stop taking losartan tablets and tell your doctor immediately or go to the casualty department of your nearest hospital: - A severe allergic reaction (rash, itching, swelling of the face, lips, mouth or throat that may cause difficulty in swallowing or breathing). This is a serious but rare side effect, which affects more than 1 out of 10,000 patients but fewer than 1 out of 1,000 patients. You may need urgent medical attention or hospitalization. The following side effects have been reported with SORTIVA:</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&bull; Dizziness. &bull; Low blood pressure (especially after excessive loss of water from the body within bloodvesselse.g. in patients with severe heart failure or under treatment with high dose diuretics).</p><p>&bull; Dose-related orthostatic effects such as lowering of blood pressure appearing when rising from a lying or sitting position.</p><p>&bull; Debility.</p><p>&bull; Fatigue.</p><p>&bull; Too little sugar in the blood (hypoglycaemia).</p><p>&bull; Too much potassium in the blood (hyperkalaemia).</p><p>&bull; Changes in kidney function including kidney failure.</p><p>&bull; Reduced number of red blood cells (anaemia).</p><p>&bull; Increase in blood urea, serum creatinine and serum potassium in patients with heart failure.</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong>:</p><p>&bull; Somnolence.</p><p>&bull; Headache.</p><p>&bull; Sleep disorders.</p><p>&bull; Feeling of increased heart rate (palpitations).</p><p>&bull; Severe chest pain (angina pectoris).</p><p>&bull; Shortness of breath (dyspnoea).</p><p>&bull; Abdominal pain.</p><p>&bull; Obstipation.</p><p>&bull; Diarrhoea.</p><p>&bull; Nausea.</p><p>&bull; Vomiting.</p><p>&bull; Hives (urticaria)</p><p>. &bull; Itching (pruritus).</p><p>&bull; Rash. &bull; Localised swelling (oedema),</p><p>&bull; Cough.</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>&bull; Hypersensitivity.</p><p>&bull; Angiooedema.</p><p>&bull; Inflammation of blood vessels (vasculitis including Hen&ouml;ch-Schonlein purpura)</p><p>&bull; Numbness or tingling sensation (paraesthesia).</p><p>&bull; Fainting (syncope).</p><p>&bull; Very rapid and irregular heartbeat (atrial fibrillation).</p><p>&bull; Brain attack (stroke).</p><p>&bull; Inflammation of the liver (hepatitis).</p><p>&bull; Elevated blood alanine aminotransferase (ALT) levels, usually resolved upon discontinuation of treatment.</p><p><strong>Not known (frequency cannot be estimated from the available data): </strong></p><p>&bull; Reduced number of thrombocytes.</p><p>&bull; Migraine.</p><p>&bull; Liver function abnormalities.</p><p>&bull; Muscle and joint pain.</p><p>&bull; Flu-like symptoms.</p><p>&bull; Back pain and urinary tract infection.</p><p>&bull; Increased sensitivity to the sun (photosensitivity).</p><p>&bull; Unexplained muscle pain with dark (tea-coloured) urine (rhabdomyolysis).</p><p>&bull; Impotence.</p><p>&bull; Inflammation of the pancreas (pancreatitis).</p><p>&bull; Low levels of sodium in the blood (hyponatraemia).</p><p>&bull; Depression. &bull; Generally feeling unwell (malaise).</p><p>&bull; Ringing, buzzing, roaring, or clicking in the ears (tinnitus).</p><p>&bull; Disturbed taste (dysgeusia).</p><p>Side effects in children are similar to those seen in adults. If you get any of the side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton Store below 30OC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What SORTIVA contains The active substance is losartan potassium.</p><p>Each SORTIVA 25 mg tablet contains 25 mg of losartan potassium.</p><p>Each SORTIVA 50 mg tablet contains 50 mg of losartan potassium.</p><p>Each SORTIVA Forte tablet contains 100 mg of losartan potassium.</p><p>Excipients:Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, purified talc, magnesium stearate, polysorbate, titanium dioxide, polyethylene glycol, hydroxypropyl methylcellulose, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                SORTIVA is supplied as a film-coated tablet. In pack of 30 film coated tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO AlQassim pharmaceutical plant Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation. Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in January 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>وسارتان (سورتیفا) ھو دواء ینتمى إلى مجموعة من الأدویة التى تسمى مضادات مستقبل أنجیوتنسین-II .أنجیوتنسین-II ھى مادة یتم إنتاجھا عن طریق الجسم وترتبط بمستقبلات على الأوعیة الدمویة، مسببة تضیق الأوعیة الدمویة. مما یسبب ارتفاع ضغط الدم. لوسارتان یمنع ارتباط مادة أنجیوتنسین-II بتلك المستقبلات، مسببا ارتخاء الأوعیة الدمویة وبالتالى انخفاض ضغط الدم. لوسارتان یعمل على تقلیل القصور الممكن حدوثھ فى وظائف الكلى عند مرضى ارتفاع ضغط الدم ومرضى السكر ). 2)من النوع- یستخدم سورتیفا فى الحالات الآتیة: &bull; لعلاج ارتفاع ضغط الدم لدى البالغین والأطفال والمراھقین من سن 18-6 سنة من العمر. &bull; لحمایة الكلى عند المرضى المصابین بارتفاع ضغط الدم ومرض السكر من النوع-2 الذین یعانون من اختلال وظائف الكلى استنادا إلى النتائج المخبریة لھؤلاء المرضى ونسبة البروتینیوریا 5.0 &le;جم فى الیوم (وھى الحالة التى یحتوى فیھا البول على كمیة غیر طبیعیة من البروتین). &bull; لعلاج المرضى المصابین بفشل قلبى مزمن فى حالة ما إذا كان العلاج عن طریق مجموعة من الأدویة تعرف باسم مثبطات الإنزیم المحول لأنجیوتنسین (مثبطات ACE وھى أدویة تستخدم لتقلیل ضغط الدم المرتفع) غیر مناسبة من وجھة نظر طبیبك المعالج. فى حالة استقرار حالة الفشل القلبى لدیك مع استخدام مثبطات ACE لا یجب تحویل علاجك إلى لوسارتان. &bull; فى حالة المرضى المصابین بارتفاع ضغط الدم وزیادة سمك البطین الأیسر، فقد تبین أن سورتیفا یقلل من خطر حدوث السكتة الدماغیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول سورتیفا فى الحالات الآتیة: &bull; إذا كنت تعانى من فرط التحسس تجاه لوسارتان أو أى من المكونات الأخرى لھذا الدواء (الموضحة بالفقرة ).6 &bull; إذا كنت فى فترة ما بعد الشھر الثالث من الحمل. (حیث أنھ من الأفضل أیضا تجنب استخدام سورتیفا فى المراحل المبكرة من الحمل- انظرى فقرة الحمل). &bull; فى حالة القصور الشدید لوظائف الكبد. &bull; إذا كان لدیك مرض السكري أو اختلال في وظائف الكلى وتقوم بتناول دواء یعمل علي خفض ضغط الدم یحتوي على ألیسكیرین. الاحتیاطات عند تناول سورتیفا التحذیرات والاحتیاطات تواصل مع طبیبك المعالج أو الصیدلى قبل تناول أقراص سورتیفا. یجب علیك إخبارطبیبك المعالج إذا كنت تعتقدین أنك حامل أو ربما تصبحین حامل. حیث أنھ لا یوصى باستخدام سورتیفا فى المرحلة المبكرة من الحمل، كما أنھ یجب عدم استخدام سورتیفا فى مرحلة ما بعد الشھر الثالث من الحمل، حیث أنھ قد یسبب ضرر جسیم لطفلك إذا ما تم استخدامھ فى تلك المرحلة (انظرى فقرة الحمل). من الضرورى علیك إخبار طبیبك المعالج قبل تناول أقراص سورتیفا فى الحالات الآتیة: - إذا كان لدیك تاریخ من الإصابة بالخزب الوعائى (وھو تورم الوجھ، الشفتین، الحلق و/أو اللسان) (انظر أیضا الفقرة 4&quot; الأعراض الجانبیة المحتملة&quot;). - إذا كنت تعانى من مشاكل بالكبد أو الكلى ً - من تقیؤ أو إسھال شدیدین مما قد یؤدى إلى نقص شدید للسوائل و/أو الأملاح فى جسمك. إذا كنت تعانى مؤخرا - إذا كنت تستخدم مدرات البول (وھى أدویة تزید من كمیة الماء المفرز خارج الجسم عن طریق الكلى) أو فى حالة اتباعك لحمیة غذائیة تحد من استخدام الملح مما یعرض جسمك إلى فقد شدید للسوائل والملح (انظر الفقرة &quot;الجرعة 3 لمجموعات خاصة من المرضى&quot;). - إذا كان معلوم أنھ لدیك تضیق أو انسداد فى الأوعیة الدمویة المؤدیة إلى الكلى أو أنك خضعت لعملیة زراعة للكلیة فى الفترة الأخیرة. - إذا كنت تعانى من قصور بوظائف الكبد (انظر الفقرة 2&quot; ما یجب مراعاتھ قبل تناول أقراص سورتیفا&quot; والفقرة &quot; 3 الجرعة لمجموعة معینة من المرضى&quot;). - إذا كنت تعانى من الفشل القلبى سواء كان مصحوبا بقصور فى الكلى أو بدونھ أو خلل شدید فى ضربات القلب بشكل متلازم قد یھدد حیاتك. یجب توخى الحذر بشكل خاص عند العلاج بشكل متزامن مع مثبطات مستقبلات بیتا. - إذا كانت لدیك مشاكل فى صمامات القلب أو عضلة القلب. - إذا كنت تعانى من أمراض القلب التاجیة (والتى تنتج عن نقص تدفق الدم بالأوعیة الدمویة الخاصة بالقلب) أو من مرض مخي وعائي (والذى ینتج عن نقص فى الدورة الدمویھ في المخ). - إذا كنت تعانى من فرط الألدوستیرون الأولى (وھو حالة یتسبب فیھا زیادة إفراز ھرمون الألدوستیرون من الغدة الكظریة، نتیجة خلل موجود بالغدة). - إذا كان لدیك زیادة فى مستوى البوتاسیوم فى الدم - الانسداد المزدوج لنظام رینین-أنجیوتنسین (RAS (باستخدام حاصرات أنجیوتنسین أو مثبطات إنزیم ACE أو ألیسكیرین یكون مصحوبا بزیادة خطورة انخفاض ضغط الدم وارتفاع مستوى البوتاسیوم فى الدم وتغیرات فى وظائف الكلى (بما في ذلك الفشل الكلوي الحاد) مقارنة باستخدام سورتیفا كعلاج منفرد. لذلك ینبغى مراقبة ضغط الدم و وظائف الكلى و الشوارد بصورة دقیقة لدى المرضى الذین یتناولون لوسارتان و بعض الأدویة الأخرى التى تؤثر على (RAS .( - إذا كنت تتناول أي من الأدویة التالیة والتي تستخدم لعلاج ارتفاع ضغط الدم: &bull; مثبطات إنزیم ACE) على سبیل المثال إنالابریل، لیسینوبریل، رامیبریل)، ولا سیما إذا كانت لدیك مشاكل في الكلى المتصلة بالسكري. &bull; ألیسكیرین قد یتحقق طبیبك من وظیفة الكلى الخاصة بك، وضغط الدم، وكمیة الشوارد (مثل البوتاسیوم) في الدم على فترات منتظمة. انظر أیضا المعلومات تحت عنوان &quot; لا تقم بتناول سورتیفا &quot;. الأطفال والمراھقین تم إجراء دراسات على استخدام سورتیفا للأطفال. لمزید من المعلومات، تواصل مع طبیبك المعالج. لا ینصح باستخدام سورتیفا للأطفال المصابین بمشاكل فى الكبد أو الكلى، أو الأطفال الأقل عمرا من 6 سنوات، نظرا لقلة المعلومات المتوفرة فى تلك المجموعات من المرضى. حدیثي الولادة الذین لدیھم تاریخ من التعرض في الرحم لعلاج سورتیفا: فى حالة وجود قلة فى البول أو انخفاض ضغط الدم, یجب الاھتمام المباشر نحو دعم ضغط الدم وترویة الكلي. قد تكون ھناك حاجة لنقل الدم أو غسیل الكلى كوسیلة لعكس انخفاض ضغط الدم و / أو استبدال لوظیفة الكلى المختلة. الأدویة الأخرى واستخدامھا مع سورتیفا قم بإخبار طبیبك المعالج إذا كنت تتناول حالیا أو تناولت مؤخرا أو ربما تتناول أى أدویة اخرى. یجب علیك الحرص بشكل خاص فى حالة تناولك لأى من الأدویة الآتیة أثناء خضوعك للعلاج بسورتیفا: - أدویة أخرى تستخدم لتقلیل ضغط الدم حیث أنھا قد تؤدى إلى تقلیل ضغط الدم بشكل زائد. ربما تتسبب أیضا بعض الأدویة الأخرى أو فصائل من الأدویة الأخرى فى تقلیل ضغط الدم مثل: مضادات الاكتئاب ثلاثیة الحلقة أو مضادات الذھان أو باكلوفین أو أمیفوستین. - لیثیوم (والذى یستخدم لعلاج أنواع معینة من الأمراض العقلیة) - الأدویة التى تحافظ على أو قد تزید من مستوى البوتاسیوم (مثل المكملات الغذائیة التى تحتوى على البوتاسیوم أو بدائل الملح التي تحتوي على البوتاسیوم أو الأدویة المدخرة للبوتاسیوم مثل بعض مدرات البول [أمیلوراید، ترایمتیرین، سبیرونولاكتون] أو الھیبارین). - مضادات الالتھاب غیر الاستیرویدیة مثل إندومیثاسین، مثبطات إنزیم 2-COX) وھى أدویة تحد من الالتھاب ویمكن استخدامھا للتخلص من الألم) حیث أنھا قد تقلل من تأثیر لوسارتان على تقلیل ضغط الدم. - الحصار المزدوج لنظام الرینین - أنجیوتنسین: یرتبط الحصار المزدوج لنظام الرینین &ndash; أنجیوتنسین باستخدام كلا من حاصرات مستقبلات الأنجیوتنسین، مثبطات الإنزیم المحول لأنجیوتنسین، أو ألیسكیرین مع زیادة مخاطر انخفاض ضغط الدم، الإغماء، ارتفاع نسبة البوتاسیوم في الدم، والتغیرات في وظائف الكلى (بما في ذلك الفشل الكلوي الحاد) مقارنة بالعلاج باستخدام أحد ھذه الأنظمة بمفرده. قم بمراقبة ضغط الدم عن كثب، وظائف الكلي، ومستوي الأملاح في المرضي الذین یتناولون لوسارتان أو أي أدویة أخري قد تؤثر علي نظام الرینین أنجیوتنسین. - مثبطات إنزیم (ACE) (الإنزیم المحول للأنجیوتنسین) (لعلاج ضغط الدم، وبعض أمراض القلب، أمراض الكلى في المرضى الذین یعانون من مرض السكري) - العلاج المتزامن ینبغي أن یقتصر على حالات محددة بشكل فردي مع مراقبة دقیقة لوظیفة الكلى. قد یحتاج طبیبك إلى تغییر الجرعة و / أو اتخاذ الاحتیاطات الأخرى: &bull; إذا كنت تتناول مثبط إنزیم ACE أو ألیسكیرین (انظر أیضا المعلومات تحت عناوین &quot;لا تقم بتناول سورتیفا &quot; و &quot;التحذیرات والاحتیاطات&quot;. - لا تتناول ألیسكیرین مع لوسارتان إذا كنت مریض بالسكرى. - تجنب تناول ألیسكیرین مع لوسارتان إذا كان لدیك خلل فى وظائف الكلى (معدل الترشیح الكبیبى &lt; ).60 مل/دقیقة إذا كان لدیك قصور فى وظائف الكلى قد یؤدى استخدام ھذه الأدویة بشكل متزامن مع لوسارتان إلى زیادة سوء وظائف الكلى. یجب تجنب استخدام الأدویة المحتویة على اللیثیوم مع لوسارتان بدون إشراف دقیق من طبیبك المعالج. حي ثیجب أن تتخذ بعض الاحتیاطات الخاصة المناسبة (مثل اختبارات الدم ). تناول سورتیفا مع الطعام والشراب یمكن تناول أقراص سورتیفا مع أو بدون الطعام. الحمل والرضاعة الحمل یجب علیك إخبار الطبیب المعالج إذا كنت تعتقدین بأنك حاملا أو ربما تصبحین حاملا. حیث أنھ سینصحك طبیبك المعالج بشكل طبیعى بالتوقف عن تناول اقراص سورتیفا قبل الحمل أو بمجرد معرفتك بالحمل وسیقوم بوصف دواء آخر بدلا من سورتیفا. ذلك لأنھ لا یوصى باستخدام سورتیفا فى المراحل المبكرة من الحمل، ویجب عدم تناولھ فیما بعد الشھر الثالث من الحمل، حیث أنھ قد یسبب ضررا جسیما للطفل إذا ما تم تناولھ فیما بعد الشھر الثالث من الحمل. الرضاعة یجب علیك إخبار الطبیب المعالج إذا كنت تقومین بإرضاع طفلك طبیعیا أو تنوین القیام بذلك. حیث أنھ لا ینصح باستخدام سورتیفا للأمھات المرضعات طبیعیا وقد یلجأ طبیبك المعالج إلى وصف علاج آخر إذا كنت ترغبین بإرضاع طفلك طبیعیا. خاصة إذا كان طفلك حدیث الولادة أو مولود قبل الأوان. اسألى الطبیب أو الصیدلى للمشورة قبل تناول ھذا الدواء. القیادة واستخدام الآلات لم یتم إجراء دراسات حول تأثیر ھذا الدواء على القدرة على قیادة السیارة و استخدام الآلات. من المستبعد أن یؤثر سورتیفا على قدرتك على قیادة السیارة أو استخدام الآلات. بالرغم من ذلك فشأنھ شأن العدید من الأدویة الأخرى لعلاج ارتفاع ضغط الدم فقد یسبب لوسارتان دوخة أو دوار لبعض الناس. لذلك إذا تعرضت للدوخة أو الدوار یجب علیك استشارة طبیبك المعالج قبل القیام بتلك الأنشطة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول ھذا الدواء تماما كما أخبرك طبیبك المعالج أو الصیدلى. إذا كنت غیر متأكد تحقق من خلال طبیبك المعالج أو الصیدلى. سوف یصف لك طبیبك المعالج الجرعة المناسبة من سورتیفا اعتمادا على حالتك وإذا كنت تتناول أدویة أخرى. یجب علیك الاستمرار فى تناول أقراص سورتیفا للمدة الزمنیة التى حددھا طبیبك المعالج وذلك للحفاظ على التحكم فى ضغط الدم. المرضى البالغین المصابین بارتفاع ضغط الدم تكون جرعة البدایة عادة 50 ملجم (قرص واحد من سورتیفا 50 ملجم) مرة واحدة یومیا. التأثیر الأقصى للدواء على إنقاص ضغط الدم یجب أن یحصل خلال من 6 -3 أسابیع من بدایة العلاج. قد یتم زیادة الجرعة فیما بعد لبعض المرضى لتصل إلى 100 ملجم مرة واحدة یومیا. فى حالة شعورك بفرط قوةأاو ضعف تأثیر لوسارتان علیك، فضلا تواصل مع طبیبك المعالج أو الصیدلى. الاستخدام في الأطفال والمراھقین الأطفال أقل من 6 سنوات من العمر لا ینصح باستخدام سورتیفا في الأطفال دون سن 6 سنوات، كما لم یظھر لھ فعالیة في ھذه الفئة العمریة . الاستخدام فى الأطفال والمراھقین (من 6 &ndash; 18 سنة من العمر) جرعة البدایة التى یوصى بھا للمرضى التى تتراوح أوزانھم ما بین 20 و 7.0 كجم ھى 50 ملجم من لوسارتان لكل كجم من وزن الجسم مرة واحدة یومیا. قد یلجأ الطبیب إلى زیادة الجرعة فى حالة عدم السیطرة على ضغط الدم. المرضى البالغین المصابین بارتفاع ضغط الدم والنوع 2 من السكر تكون جرعة البدایة عادة 50 ملجم (قرص واحد من سورتیفا 50 ملجم) مرة واحدة یومیا. قد یتم زیادة الجرعة فیما بعد إلى 100 ملجم مرة واحدة یومیا اعتماد على استجابة ضغط دمك للدواء. قد یتم تناول لوسارتان مع أدویة أخرى تستخدم لإنقاص ضغط الدم (مثل مدرات البول و مغلقات قنوات الكالسیوم ومغلقات مستقبلات ألفا أو بیتا والأدویة التى تعمل على الجھاز العصبى المركزى) كما قد یتم تناولھ مع الإنسولین وأدویة أخرى شائعة الاستخدام لإنقاص مستوى الجلوكوز بالدم (مثل السلفونیل یوریا والجلیتازونات ومثبطات إنزیم جلوكوسیدیز). المرضى البالغین المصابین بالفشل القلبى تكون جرعة البدایة عادة 5.12 ملجم من لوسارتان مرة واحدة یومیا. بشكل عام یجب زیادة الجرعة أسبوعیا بشكل تدریجى 5.12)بمعنى ملجم یومیا ثم 25 ملجم یومیا ثم 50 ملجم یومیا) إلى أن تصل إلى الجرعة المزمنة المعتادة وھى ملجم مرة 50 ً, والتى یمكن تحملھا من قبل المریض. واحدة یومیا الجرعة القصوى من لوسارتان ھى 150 3 ملجم (مثلا أقراص من سورتیفا 50 ملجم أو قرص واحد من سورتیفا فورت 100 ملجم مع قرص واحد من سورتیفا 50 ملجم ) مرة واحدة یومیا. فى حالة علاج الفشل القلبى عادة یتم استخدام لوسارتان مع مدر للبول (وھو دواء یستخدم لیزید من كمیة الماء المفرز من الجسم عن طریق الكلى) و/ أو دیجیتالیس (وھو دواء یزید من كفاءة وقوة القلب) و/ أو مثبطات البیتا. الجرعة لمجموعات خاصة من المرضى قد یصف الطبیب جرعة أقل من المعتاد خاصة فى بدایة العلاج لبعض المرضى مثل المرضى الخاضعین للعلاج بجرعات كبیرة من مدرات البول أو المرضى المصابین بفشل الكبد أو كبار السن من المرضى ما فوق 75 سنة من العمر. لا ینصح باستخدام لوسارتان للمرضى المصابین بقصور حاد فى الكبد (انظر الفقرة &quot;توقف عن تناول سورتیفا&quot;). طریقة تناول أقراص سورتیفا یجب ابتلاع قرص سورتیفا مع كوب من الماء. حاول أن تتناول الجرعة الیومیة فى نفس الوقت من كل یوم. من الضرورى أن تستمر فى تناول أقراص سورتیفا ما لم یخبرك طبیبك المعالج بخلاف ذلك. فى حالة تناولك لأقراص سورتیفا اكثر مما ینبغى إذا قمت بتناول أقراص سورتیفا بشكل زائد بطریق الخطأ، تواصل مع طبیبك المعالج فورا. أعراض الجرعة الزائدة ھى انخفاض ضغط الدم أو زیادة معدل ضربات القلب أو من الممكن نقص معدل ضربات القلب. فى حالة نسیان تناول أقراص سورتیفا إذا فقدت أو نسیت الجرعة الیومیة عن طریق الخطأ، فقط تناول الجرعة التالیة كما ھو معتاد. لا تقم بتناول جرعة مضاعفة لتعویض الجرعة المفقودة. إذا كانت لدیك أى أسئلة إضافیة حول استخدام ھذا الدواء، اسأل الطبیب أو الصیدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة، ھذا الدواء قد یسبب آثار جانبیة، وإن لم تكن تحدث لكل من یتناول ھذا الدواء. إذا تعرضت لأى من الأعراض الجانبیة الآتیة توقف عن تناول أقراص سورتیفا وأخبر طبیبك المعالج فى الحال أو توجھ إلى قسم الاصابات بأقرب مستشفى: - تفاعلات تحسسیة حادة (طفح الجلدى ، حكة ، تورم الوجھ، الشفتین، الفم أو الحلق مما یسبب صعوبة فى البلع أو التنفس). ھذا من الآثار الجانبیة الخطیرة ولكنھ نادر الحدوث، والذى یصیب أكثر من واحد لكل 000,10 مریض ولكن أقل من واحد لكل 1000 مریض. قد تحتاج إلى تدخل طبى عاجل أو التنویم داخل المستشفى. تم الإبلاغ عن الأعراض الجانبیة الآتیة مع استخدام سورتیفا: أعراض جانبیة شائعة الحدوث (تصیب حتى 1 من كل 10 مستخدمین لھذا الدواء): &bull; دوخة. &bull; انخفاض ضغط الدم (خصوصا بعد الفقدان المفرط للماء من الجسم خلال الأوعیة الدمویة مثلما یحدث للمرضى المصابین بالفشل القلبى الحاد أو للمرضى الخاضعین للعلاج بجرعات كبیرة من مدرات البول). &bull; التأثیرات التي تظھر عند القیام و المرتبطة بالجرعة مثل انخفاض ضغط الدم بعد الوقوف من الجلوس أو الرقود. &bull; وھن. &bull; إرھاق. &bull; انخفاض مستوى السكر بالدم (ھیبوجلایسیمیا). &bull; ارتفاع مستوى البوتاسیوم بالدم (ھیبركالیمیا). &bull; تغیرات فى وظائف الكلى بما فیھا الفشل الكلوى. &bull; انخفاض عدد خلایا الدم الحمراء (أنیمیا). &bull; زیادة الیوریا وزیادة الكریاتینین وزیادة البوتاسیوم بالدم عند المرضى المصابین بالفشل القلبى. أعراض جانبیة غیر شائعة الحدوث (تصیب حتى 1 من كل 100 مستخدم لھذا الدواء): &bull; نعاس. &bull; صداع. &bull; اضطرابات فى النوم. &bull; الشعور بزیادة ضربات القلب (خفقان). &bull; ألم شدید بالصدر (الذبحة الصدریة). &bull; ضیق في التنفس. &bull; ألم بالبطن. &bull; إمساك مستعص. &bull; إسھال. &bull; غثیان. &bull; تقیؤ. &bull; الشرى. &bull; حكة. &bull; طفح جلدى. &bull; تورم موضعى (استسقاء). &bull; سعال . أعراض جانبیة نادرة الحدوث (تصیب حتى 1 من كل 1000 مستخدم لھذا الدواء): &bull; تفاعلات تحسسیة. &bull; ذمة وعائیة. &bull; التھاب الأوعیة الدمویة. &bull; تنمیل أو إحساس بوخز الإبر. &bull; الإغماء (الغشیان). &bull; عدم انتظام وسرعة حادة فى ضربات القلب (الرجفان الأذیني). &bull; السكتة الدماغیة. &bull; التھاب الكبد. &bull; ارتفاع مستوى إنزیم ألانین ترانسفیریز الأمینى بالدم (ALT ،(والذى یزول عند التوقف عن تناول العلاج. أعراض جانبیة غیر معروفة (معدل حدوثھا لا یمكن تقدیره من المعلومات المتاحة): &bull; انخفاض عدد الصفائح الدمویة. &bull; صداع نصفى. &bull; خلل فى وظائف الكبد. &bull; ألم بالعضلات والمفاصل. &bull; أعراض شبیھة بأعراض الأنفلونزا. &bull; آلام الظھر والتھاب المسالك البولیة. &bull; زیادة الحساسیة للشمس. &bull; ألم غیر مبرر في العضلات مع تغیر لون البول إلى اللون القاتم (لون الشاى)علامة على انحلال العضلات. &bull; عجز جنسي. &bull; التھاب البنكریاس. &bull; انخفاض مستوى الصودیوم فى الدم. &bull; اكتئاب. &bull; الشعور العام بتوعك. &bull; رنین أو طنین فى الأذنین. &bull; خلل في الإحساس بالطعم (خلل التذوق). الآثار الجانبیة فى الأطفال شبیھة بتلك الموجودة فى البالغین. إذا تعرضت لأى أعراض جانبیة، تواصل مع طبیبك المعالج أو الصیدلى أو الممرض. بما فى ذلك أى أعراض جانبیة لم یتم ذكرھا فى ھذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ الدواء بعیدا عن متناول ونظر الاطفال. لا تستعمل أقراص سورتیفا بعد انتھاء تاریخ الصلاحیة المدون على العبوة. یتم تخزینھ فى درجة أقل من 30 درجة مئویة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحتوى أقراص سورتیفا على: المكونات الفعالة: یحتوي كل قرص سورتیفا 25 ملغم على 25 ملجم لوسارتان بوتاسیوم. یحتوي كل قرص سورتیفا 50 ملغم على 50 ملجم لوسارتان بوتاسیوم. یحتوي كل قرص سورتیفا فورت على 100 ملجم لوسارتان بوتاسیوم. المكونات الغیر فعالة: كریستالات السیلیلوز الدقیقة، كروسكمالوز الصودیوم، ثنائي أكسید السیلیكون الغرواني، تالك منقى، ستایرات المغنیسیوم، بولي سوربات، ثنائي أكسید التیتنیوم، بولي إیثیلین جلایكول، ھیدروكسي بروبیل میثیل سیللیلوز، ماء منقى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>یتوافر سورتیفا على ھیئة أقراص مغلفة بطبقة رقیقة تحتوي كل عبوة على . 30 قرصا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج الدوائية &nbsp;مصنع الأدوية بالقصيم &nbsp;<br />الشركة السعودية للصناعات الدوائية والمستلزمات الطبية. &nbsp;<br />المملكة العربية السعودية. &nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على ھذه النشرة بتاریخ ینایر . 2017

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sortiva® 25 mg film-coated tablets
Sortiva® 50 mg film-coated tablets
Sortiva Forte® 100 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each SORTIVA 25 mg tablet contains 25 mg of losartan potassium.
Each SORTIVA 50 mg tablet contains 50 mg of losartan potassium.
Each SORTIVA Forte tablet contains 100 mg of losartan potassium.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Treatment of essential hypertension in adults and in children and adolescents 6-18 years of age. &bull; Treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus with proteinuria &ge; 0.5 g/day as part of an antihypertensive treatment (see sections 4.3, 4.4, 4.5, and 5.1). &bull; Treatment of chronic heart failure in adult patients when treatment with Angiotensin converting enzyme (ACE) inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication. Patients with heart failure who have been stabilised with an ACE inhibitor should not be switched to losartan. The patients should have a left ventricular ejection fraction 40% and should be clinically stable and on an established treatment regimen for chronic heart failure. &bull; Reduction in the risk of stroke in adult hypertensive patients with left ventricular hypertrophy documented by ECG (see section 5.1 LIFE study, Race).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Hypertension The usual starting and maintenance dose is 50 mg once daily for most patients. The&nbsp;maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily (in the morning). Losartan may be administered with other antihypertensive agents, especially with diuretics (e.g. hydrochlorothiazide) (see sections 4.3, 4.4, 4.5, and 5.1). Hypertensive type II diabetic patients with proteinuria &ge; 0.5 g/day The usual starting dose is 50 mg once daily. The dose may be increased to 100 mg once daily based on blood pressure response from one month onwards after initiation of therapy. Losartan may be administered with other antihypertensive agents (e.g. diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used hypoglycemic agents (e.g.sulfonylureas, glitazones and glucosidase inhibitors). Heart Failure The usual initial dose of losartan in patients with heart failure is 12.5 mg once daily. The dose should generally be titrated at weekly intervals (i.e. 12.5 mg daily, 25 mg daily, 50 mg daily, 100 mg daily, up to a maximum dose of 150 mg once daily) as tolerated by the patient. Reduction in the risk of stroke in hypertensive patients with left ventricular hypertrophy documented by ECG The usual starting dose is 50 mg of losartan once daily. A low dose of hydrochlorothiazide should be added and/or the dose of losartan should be increased to 100 mg once daily based on blood pressure response. Special populations Use in patients with intravascular volume depletion: For patients with intravascular volume-depletion (e.g. those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered (see section 4.4). Use in patients with renal impairment and haemodialysis patients: No initial dosage adjustment is necessary in patients with renal impairment and in haemodialysis patients. Use in patients with hepatic impairment: A lower dose should be considered for patients with a history of hepatic impairment. There is no therapeutic experience in patients with severe hepatic impairment. Therefore, losartan is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 4.4). Paediatric population 6 months &ndash; less than 6 years&nbsp;The safety and efficacy of children aged 6 months to less than 6 years has not been established. Currently available data are described in sections 5.1 and 5.2 but no recommendation on posology can be made. 6 years to 18 years For patients who can swallow tablets, the recommended dose is 25 mg once daily in patients &gt;20 to 50 kg, the usual dose is 50 mg once daily. In exceptional cases the dose can be adjusted to a maximum of 100 mg once daily. Doses above 1.4 mg/kg (or in excess of 100 mg) daily have not been studied in paediatric patients. Losartan is not recommended for use in children under 6 years old, as limited data are available in these patient groups. It is not recommended in children with glomerular filtration rate &lt; 30 ml/min/1.73 m2 , as no data are available (see also section 4.4). Losartan is also not recommended in children with hepatic impairment (see also section 4.4). Use in Elderly Although consideration should be given to initiating therapy with 25 mg in patients over 75 years of age, dosage adjustment is not usually necessary for the elderly.</p><p><strong>Method of administration</strong></p><p>Losartan tablets should be swallowed with a glass of water. Losartan tablets may be administered with or without food</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 4.4
and 6.1.
• 2nd and 3rd trimester of pregnancy (see section 4.4 and 4.6).
• Severe hepatic impairment.
• The concomitant use of losartan with aliskiren-containing products is contraindicated in
patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2
) (see
sections 4.5 and 5.1). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity </u></p><p>Angioedema. Patients with a history of angioedema (swelling of the face, lips, throat, and/or tongue) should be closely monitored (see section 4.8).</p><p>Hypotension and Electrolyte/Fluid Imbalance Symptomatic hypotension, especially after the first dose and after increasing of the dose, may occur in patients who are volume- and/or sodium-depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting. These conditions should be corrected prior to administration of losartan, or a lower starting dose should be used (see section 4.2). This also applies to children 6 to 18 years of age. Electrolyte imbalances Electrolyte imbalances are common in patients with renal impairment, with or without diabetes, and should be addressed. In a clinical study conducted in type 2 diabetic patients with nephropathy, the incidence of hyperkalaemia was higher in the group treated with losartan as compared to the placebo group (see section 4.8). Therefore, the plasma concentrations of potassium as well as creatinine clearance values should be closely monitored, especially patients with heart failure and a creatinine clearance between 30-50 ml/min should be closely monitored. The concomitant use of potassium-sparing diuretics, potassium supplements and potassium-containing salt substitutes with losartan is not recommended (see section 4.5).</p><p>Hepatic impairment</p><p>Based on pharmacokinetic data which demonstrate significantly increased plasma concentrations of losartan in cirrhotic patients, a lower dose should be considered for patients with a history of hepatic impairment. There is no therapeutic experience with losartan in patients with severe hepatic impairment. Therefore losartan must not be administered in patients with severe hepatic impairment (see sections 4.2, 4.3 and 5.2). Losartan is not recommended in children with hepatic impairment (see section 4.2).</p><p>Renal impairment</p><p>As a consequence of inhibiting the renin-angiotensin system, changes in renal function including renal failure have been reported (in particular, in patients whose renal function is dependent on the renin- angiotensin-aldosterone system such as those with severe cardiac insufficiency or pre-existing renal dysfunction). As with other medicinal products that affect the reninangiotensin- aldosterone system, increases in blood urea and serum creatinine have also been reported in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney; these changes in renal function may be reversible upon discontinuation of therapy. Losartan should be used with caution in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. Use in paediatric patients with renal impairment Losartan is not recommended in children with glomerular filtration rate &lt; 30 ml/min/1.73 m2 as no data are available (see section 4.2). Renal function should be regularly monitored during treatment with losartan as it may deteriorate. This applies particularly when losartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function. Concomitant use of losartan and ACE-inhibitors has shown to impair renal function. Therefore, concomitant use is not recommended (see section 4.5). Renal transplantation There is no experience in patients with recent kidney transplantation. Primary hyperaldosteronism Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of losartan is not recommended. Coronary heart disease and cerebrovascular disease As with any antihypertensive agents, excessive blood pressure decrease in patients with ischaemic cardiovascular and cerebrovascular disease could result in a myocardial infarction or stroke. Heart failure In patients with heart failure, with or without renal impairment, there is - as with other medicinal products acting on the renin-angiotensin system - a risk of severe arterial hypotension, and (often acute) renal impairment. There is no sufficient therapeutic experience with losartan in patients with heart failure and concomitant severe renal impairment, in patients with severe heart failure (NYHA class IV) as well as in patients with heart failure and symptomatic lifethreatening cardiac arrhythmias. Therefore, losartan should be used with caution in these patient groups. The combination of losartan with a beta-blocker should be used with caution (see section 5.1). Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Pregnancy Losartan should not be initiated during pregnancy. Unless continued losartan therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with losartan should be stopped immediately, and if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). Other warnings and precautions As observed for angiotensin converting enzyme inhibitors, losartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population. Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia, and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Other antihypertensive agents may increase the hypotensive action of losartan. Concomitant use with other substances which may induce hypotension as an adverse reaction (like tricyclic antidepressants, antipsychotics, baclofen and amifostine) may increase the risk of hypotension. Losartan is predominantly metabolised by cytochrome P450 (CYP) 2C9 to the active carboxy-acid metabolite. In a clinical trial it was found that fluconazole (inhibitor of CYP2C9) decreases the exposure to the active metabolite by approximately 50%. It was found that concomitant treatment of losartan with rifampicin (inducer of metabolism enzymes) gave a 40% reduction in plasma concentration of the active metabolite. The clinical relevance of this effect is unknown. No difference in exposure was found with concomitant treatment with fluvastatin (weak inhibitor of CYP2C9). As with other medicinal products that block angiotensin II or its effects, concomitant use of other medicinal products which retain potassium (e.g. potassium-sparing diuretics: amiloride, triamterene, spironolactone) or may increase potassium levels (e.g. heparin), potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium. Comedication is not advisable. Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Very rare cases have also been reported with angiotensin II receptor antagonists. Co-administration of lithium and losartan should be undertaken with caution. If this combination proves essential, serum lithium level monitoring is recommended during concomitant use. When angiotensin II antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid at anti-inflammatory doses and nonselective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter. Clinical trial data have shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia, and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4, and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Pregnancy category: D. The use of losartan is not recommended during the first trimester of pregnancy (see section 4.4). The use of losartan is contraindicated during the 2nd and 3rd trimester of pregnancy (see section 4.3 and 4.4). Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of medicinal products. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with losartan should be stopped immediately and, if appropriate, alternative therapy should be started. Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3). Should exposure to losartan have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken losartan should be closely observed for hypotension (see also section 4.3 and 4.4). Lactation Because no information is available regarding the use of losartan during breastfeeding, losartan is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, when driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy, in particular during initiation of treatment or when the dose is increased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Losartan has been evaluated in clinical studies as follows: &bull; In a controlled clinical trial in &gt; 3,000 adult patients 18 years of age and older for essential hypertension. &bull; In a controlled clinical trial in 177 hypertensive paediatric patients 6 to 16 years of age. &bull; In a controlled clinical trial in &gt; 9,000 hypertensive patients 55 to 80 years of age with left ventricular hypertrophy (see LIFE Study, section 5.1). &bull; In controlled clinical trials in &gt; 7,700 adult patients with chronic heart failure (see ELITE I, ELITE II, and HEAAL study, section 5.1). &bull; In a controlled clinical trial in &gt; 1,500 type 2 diabetic patients 31 years of age and older with proteinuria (see RENAAL study, section 5.1). In these clinical trials, the most common adverse event was dizziness. The frequency of adverse reactions listed below is defined using the following convention: Very common ( &ge;1/10); common ( &ge;1/100, to &lt; 1/10); uncommon ( &ge;1/1,000, to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p><strong>Table 1. The frequency of adverse reactions identified from placebo-controlled clinical studies and post marketing experience</strong></p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Adverse reaction</td><td rowspan="1" colspan="4">Frequency of adverse reaction by indication&nbsp;</td><td>other</td></tr><tr><td>&nbsp;</td><td>Hypertention</td><td>Hypertensive patient with left-ventricular hypertrophy</td><td>Chronic Heart Failure</td><td>Hypertention and type 2 diabetes with renal disease</td><td>Post-markting experiance&nbsp;</td></tr><tr><td colspan="6"><u>Blood and lymphatic system disorder&nbsp;</u></td></tr><tr><td>Anemia&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Common</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>Thrombocytopenia&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Immune system disorder&nbsp;</u></td></tr><tr><td>hypersensivity reactions, anaphylactic reactions , angiooedema *, and vasculitis **</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>rare</td></tr><tr><td colspan="6">Psychiatric disorder&nbsp;</td></tr><tr><td>depression</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Nervous system disorder&nbsp;</u></td></tr><tr><td>dizzines</td><td>common</td><td>common</td><td>common</td><td>common</td><td>&nbsp;</td></tr><tr><td>somnolence&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>headache</td><td>uncommon</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>sleep disorder</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>paraesthesia</td><td>&nbsp;</td><td>&nbsp;</td><td>rare</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>migraine</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>dysgeusia</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Ear and labyrinth disorder&nbsp;</u></td></tr><tr><td>vertigo</td><td>common</td><td>common</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>tinnitus</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Cardiac disorder&nbsp;</u></td></tr><tr><td>Palpitations&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>angina pectoris</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>syncope</td><td>&nbsp;</td><td>&nbsp;</td><td>rare</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>atrial fibrillation&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>rare</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>cerebrovascular accident&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>rare</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="6"><u>Vascular disorders&nbsp;</u></td></tr><tr><td>(orthostatic) hypotention ( Including dose- related orthostatic effects)&nbsp;<sup>║</sup></td><td>Uncommon</td><td>&nbsp;</td><td>common</td><td>common</td><td>&nbsp;</td></tr><tr><td colspan="6"><u>Respiratory, thoracic and mediastinal disorder&nbsp;</u></td></tr><tr><td>dyspnoea</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>cough</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Gastrointestinal disorders&nbsp;</u></td></tr><tr><td>abdominal pain</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>obstipation</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>diarrhoea&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>nausea&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>vomiting</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="6"><u>Hepatobiliary disorders&nbsp;</u></td></tr><tr><td>pancreatitis&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>hepatitis&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>rare</td></tr><tr><td>liver function abnormalities&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6">Skin and subcutaneous tissue disorders&nbsp;</td></tr><tr><td>Urticaria&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>pruritus&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>rash</td><td>&nbsp;</td><td>&nbsp;</td><td>uncommon</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>photosensitivity</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6">Musculoskeletal and connective tissue disorders</td></tr><tr><td>myalgia</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>arthralgia</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>rhabdomyolysis</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Renal and urinary disorders&nbsp;</u></td></tr><tr><td>renal impairment&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>common</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>renal failure</td><td>&nbsp;</td><td>&nbsp;</td><td>common</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="6"><u>Reproductive system and breaset disorders</u></td></tr><tr><td>erectile dysfunction \ impotence</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Genral disorder and administration site conditions&nbsp;</u></td></tr><tr><td>asthenia</td><td>uncommon</td><td>common</td><td>uncommon</td><td>common</td><td>&nbsp;</td></tr><tr><td>fatigue</td><td>uncommon</td><td>common</td><td>uncommon</td><td>common</td><td>&nbsp;</td></tr><tr><td>oedma</td><td>uncommon</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>malaise</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td colspan="6"><u>Investigations&nbsp;</u></td></tr><tr><td>hyperkalaemia</td><td>common</td><td>&nbsp;</td><td>uncommon &dagger;</td><td>common&Dagger;</td><td>&nbsp;</td></tr><tr><td>Increased alanine aminotransferase ( ALT)<sup>&nbsp;&sect;</sup></td><td>rare</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>increase in blood urea, serum creatinine , and serum potassium</td><td>&nbsp;</td><td>&nbsp;</td><td>common</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>hyponatraemia</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>frequency not known</td></tr><tr><td>hypoglycaemia</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>common</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>*Including swelling of the larynx, glottis, face, lips, pharynx, and/or tongue (causing airway obstruction); in some of these patients angiooedema had been reported in the past in connection with the administration of other medicines, including ACE inhibitors</p><p>**Including Henoch-Sch&ouml;nlein purpura</p><p>║Especially in patients with intravascular depletion, e.g. patients with severe heart failure or under treatment with high dose diuretics</p><p>&dagger; Common in patients who received 150 mg losartan instead of 50 mg</p><p>&Dagger; In a clinical study conducted in type 2 diabetic patients with nephropathy, 9.9% of patients treated with Losartan tablets developed hyperkalaemia &gt;5.5 mmol/l and 3.4% of patients treated with placebo</p><p>&sect; Usually resolved upon discontinuation</p><p>The following additional adverse reactions occurred more frequently in patients who received losartan than placebo (frequencies not known): back pain, urinary tract infection, and flu-like symptoms.</p><p>&nbsp;</p><p><em>Renal and urinary disorders: </em></p><p>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function including renal failure have been reported in patients at risk; these changes in renal function may be reversible upon discontinuation of therapy (see section 4.4).</p><p><u>Paediatric population </u></p><p>The adverse reaction profile for paediatric patients appears to be similar to that seen in adult patients. Data in the paediatric population are limited.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of intoxication Limited data are available with regard to overdose in humans. The most likely manifestation of overdose would be hypotension and tachycardia. Bradycardia could occur from parasympathetic (vagal) stimulation. Treatment of intoxication If symptomatic hypotension should occur, supportive treatment should be instituted. Measures are depending on the time of medicinal product intake and kind and severity of symptoms. Stabilisation of the cardiovascular system should be given priority. After oral intake, the administration of a sufficient dose of activated charcoal is indicated. Afterwards, close monitoring of the vital parameters should be performed. Vital parameters should be corrected if necessary. Neither losartan nor the active metabolite can be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists, plain ATC code: C09CA01 5.1 Pharmacodynamic properties Losartan is a synthetic oral angiotensin-II receptor (type AT1) antagonist. Angiotensin II, a potent vasoconstrictor, is the primary active hormone of the renin/angiotensin system and an important determinant of the pathophysiology of hypertension. Angiotensin II To report any side effect(s):  The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662 o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. o Toll free phone: 8002490000 o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc binds to the AT1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland, kidneys and the heart) and elicits several important biological actions, including vasoconstriction and the release of aldosterone. Angiotensin II also stimulates smooth muscle cell proliferation. Losartan selectively blocks the AT1 receptor. In vitro and in vivo losartan and its pharmacologically active carboxylic acid metabolite E-3174 block all physiologically relevant actions of angiotensin II, regardless of the source or route of its synthesis. Losartan does not have an agonist effect nor does it block other hormone receptors or ion channels important in cardiovascular regulation. Furthermore losartan does not inhibit ACE (kininase II), the enzyme that degrades bradykinin. Consequently, there is no potentiation of undesirable bradykinin-mediated effects. During administration of losartan, removal of the angiotensin II negative feedback on renin secretion leads to increased plasma renin activity (PRA). Increase in the PRA leads to an increase in angiotensin II in plasma. Despite these increases, Antihypertensive activity and suppression of plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade. After discontinuation of losartan, PRA and angiotensin II values fell within three days to the baseline values. Both losartan and its principal active metabolite have a far greater affinity for the AT1- receptor than for the AT2-receptor. The active metabolite is 10- to 40- times more active than losartan on a weight for weight basis. Hypertension Studies In controlled clinical studies, once-daily administration of losartan to patients with mild to moderate essential hypertension produced statistically significant reductions in systolic and diastolic blood pressure. Measurements of blood pressure 24 hours post-dose relative to 5 &ndash; 6 hours post-dose demonstrated blood pressure reduction over 24 hours; the natural diurnal rhythm was retained. Blood pressure reduction at the end of the dosing interval was 70 &ndash; 80 % of the effect seen 5-6 hours post-dose. Discontinuation of losartan in hypertensive patients did not result in an abrupt rise in blood pressure (rebound). Despite the marked decrease in blood pressure, losartan had no clinically significant effects on heart rate. Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients. LIFE-Study The Losartan Intervention For Endpoint Reduction in Hypertension [LIFE] study was a randomised, triple-blind, active-controlled study in 9193 hypertensive patients aged 55 to 80 years with ECG-documented left-ventricular hypertrophy. Patients were randomised to once daily losartan 50 mg or once daily atenolol 50 mg. If goal blood pressure (&lt; 140/90 mmHg) was not reached, hydrochlorothiazide (12.5 mg) was added first and, if needed, the dose of losartan or atenolol was then increased to 100 mg once daily. Other antihypertensives, with the exception of ACE-inhibitors, angiotensin II antagonists or beta-blockers were added if necessary to reach the goal blood pressure. The mean length of follow up was 4.8 years. The primary endpoint was the composite of cardiovascular morbidity and mortality as measured by a reduction in the combined incidence of cardiovascular death, stroke and myocardial infarction. Blood pressure was significantly lowered to similar levels in the two groups. Treatment with losartan resulted in a 13.0% risk reduction (p=0.021, 95 % confidence interval 0.77-0.98) compared with atenolol for patients reaching the primary composite endpoint. This was mainly attributable to a reduction of the incidence of stroke. Treatment with losartan reduced the risk of stroke by 25% relative to atenolol (p=0.001 95% confidence interval 0.63-0.89). The rates of cardiovascular death and myocardial infarction were not significantly different between the treatment groups. Race In the LIFE-Study black patients treated with losartan had a higher risk of suffering the primary combined endpoint, i.e. a cardiovascular event (e.g. cardiac infarction, cardiovascular death) and especially stroke, than the black patients treated with atenolol. Therefore the results observed with losartan in comparison with atenolol in the LIFE study with regard to cardiovascular morbidity/mortality do not apply for black patients with hypertension and left ventricular hypertrophy. RENAAL Study The Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist losartan RENAAL study was a controlled clinical study conducted worldwide in 1513 Type 2 diabetic patients with proteinuria, with or without hypertension. 751 patients were treated with losartan. The objective of the study was to demonstrate a nephroprotective effect of losartan potassium over and above the benefit of lowering blood pressure. Patients with proteinuria and a serum creatinine of 1.3 &ndash; 3.0 mg/dl were randomised to receive losartan 50 mg once a day, Titrated if necessary, to achieve blood pressure response, or to placebo, on a background of conventional antihypertensive therapy excluding ACE-inhibitors and angiotensin II antagonists. Investigators were instructed to titrate the study medication to 100 mg daily as appropriate; 72 % of patients were taking the 100 mg daily dose for the majority of the time. Other antihypertensive agents (diuretics, calcium antagonists, alpha- and betareceptor blockers and also centrally acting antihypertensives) were permitted as supplementary treatment depending on the requirement in both groups. Patients were followed up for up to 4.6 years (3.4 years on average). The primary endpoint of the study was a composite endpoint of doubling of the serum creatinine end-stage renal failure (need for dialysis or transplantation) or death. The results showed that the treatment with losartan (327 events) as compared with placebo (359 events) resulted in a 16.1 % risk reduction (p = 0.022) in the number of patients reaching the primary composite endpoint. For the following individual and combined components of the primary endpoint, the results showed a significant risk reduction in the group treated with losartan: 25.3 % risk reduction for doubling of the serum creatinine (p = 0.006); 28.6 % risk reduction for end-stage renal failure (p = 0.002); 19.9 % risk reduction for end-stage renal failure or death (p = 0.009); 21.0 % risk reduction for doubling of serum creatinine or end-stage renal failure (p = 0.01). All-cause mortality rate was not significantly different between the two treatment groups. In this study losartan was generally well tolerated, as shown by a therapy discontinuation rate on account of adverse reactions that was comparable to the placebo group. HEAAL Study The Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan (HEAAL) study was a controlled clinical study conducted worldwide in 3834 patients aged 18 to 98 years with heart failure (NYHA Class II-IV) who were intolerant of ACE inhibitor treatment. Patients were randomised to receive losartan 50 mg once a day or losartan 150 mg, on a background of conventional therapy excluding ACE-inhibitors. Patients were followed for over 4 years (median 4.7 years). The primary endpoint of the study was a composite endpoint of all cause death or hospitalisation for heart failure. The results showed that treatment with 150 mg losartan (828 events) as compared with 50 mg losartan (889 events) resulted in a 10.1% risk reduction (p=0.027 95% confidence interval 0.82-0.99) in the number of patients reaching the primary composite endpoint. This was mainly attributable to a reduction of the incidence of hospitalisation for heart failure. Treatment with 150 mg losartan reduced the risk of hospitalisation for heart failure by 13.5% relative to 50 mg losartan (p=0.025 95% confidence interval 0.76-0.98). The rate of all cause death was not significantly different between the treatment groups. Renal impairment, hypotension, and hyperkalaemia were more common in the 150 mg group than in the 50 mg group, but these adverse events did not lead to significantly more treatment discontinuations in the 150 mg group. ELITE I and ELITE II Studies In the ELITE Study carried out over 48 weeks in 722 patients with heart failure (NYHA Class II-IV), no difference was observed between the patients treated with losartan and those treated with captopril was observed with regard to the primary endpoint of a longterm change in renal function. The observation of the ELITE I Study that compared with captopril, losartan reduced the mortality risk, was not confirmed in the subsequent ELITE II Study, which is described in the following. In the ELITE II Study losartan 50 mg once daily (starting dose 12.5 mg, increased to 25 mg, then 50 mg once daily) was compared with captopril 50 mg three times daily (starting dose 12.5 mg, increased to 25 mg and then to 50 mg three times daily). The primary endpoint of this prospective study was the all-cause mortality. In this study, 3152 patients with heart failure (NYHA Class II-IV) were followed for almost two years (median: 1.5 years) in order to determine whether losartan is superior to captopril in reducing all cause mortality. The primary endpoint did not show any statistically significant difference between losartan and captopril in reducing all-cause mortality. In both comparator-controlled (not placebo-controlled) clinical studies on patients with heart failure the tolerability of losartan was superior to that of captopril, measured on the basis of a significantly lower rate of discontinuations of therapy on account of adverse reactions and a significantly lower frequency of cough. An increased mortality was observed in ELITE II in the small subgroup (22% of all HF patients) taking beta-blockers at baseline. Dual Blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomized, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of endorgan damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy. These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy. ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group. Paediatric Population Paediatric Hypertension The antihypertensive effect of losartan was established in a clinical study involving 177 hypertensive paediatric patients 6 to 16 years of age with a body weight &gt; 20 kg and a glomerular filtration rate &gt; 30 ml/min/1.73 m2. Patients who weighed &gt; 20 kg to &lt; 50 kg received either 2.5, 25 or 50 mg of losartan daily and patients who weighed &gt; 50 kg received either 5, 50 or 100 mg of losartan daily. At the end of three weeks, losartan administration once daily lowered trough blood pressure in a dose-dependent manner. Overall, there was a dose-response. The dose-response relationship became very obvious in the low dose group compared to the middle dose group (period I: -6.2 mmHg vs. - 11.65 mmHg), but was attenuated when comparing the middle dose group with the high dose group (period I: -11.65 mmHg vs. -12.21 mmHg). The lowest doses studied, 2.5 mg and 5 mg, corresponding to an average daily dose of 0.07 mg/ kg, did not appear to offer consistent antihypertensive efficacy. These results were confirmed during period II of the study where patients were randomised to continue losartan or placebo, after three weeks of treatment. The difference in blood pressure increase as compared to placebo was largest in the middle dose group (6.70 mmHg middle dose vs. 5.38 mmHg high dose). The rise in trough diastolic blood pressure was the same in patients receiving placebo and in those continuing losartan at the lowest dose in each group, again suggesting that the lowest dose in each group did not have significant antihypertensive effect. Long-term effects of losartan on growth, puberty and general development have not been studied. The long-term efficacy of antihypertensive therapy with losartan in childhood to reduce cardiovascular morbidity and mortality has also not been established. In hypertensive (N=60) and normotensive (N=246) children with proteinuria, the effect of losartan on proteinuria was evaluated in a 12-week placebo- and active-controlled (amlodipine) clinical study. Proteinuria was defined as urinary protein/creatinine ratio of &ge;0.3. The hypertensive patients (ages 6 through 18 years) were randomised to receive either losartan (n=30) or amlodipine (n=30). The normotensive patients (ages 1 through 18 years) were randomised to receive either losartan (n=122) or placebo (n=124). Losartan was given at doses of 0.7 mg/kg to 1.4 mg/kg (up to maximum dose of 100 mg per day). Amlodipine was given at doses of 0.05 mg/kg to 0.2 mg/kg (up to a maximum dose of 5 mg per day). Overall, after 12 weeks of treatment, patients receiving losartan experienced a statistically significant reduction from baseline in proteinuria of 36% versus 1% increase in placebo/amlodipine group (p &le;0.001). Hypertensive patients receiving losartan experienced a reduction from baseline proteinuria of -41.5% (95% CI -29.9;-51.1) versus +2.4% (95% CI -22.2;14.1) in the amlodipine group. The decline in both systolic blood pressure and diastolic blood pressure was greater in the losartan group (- 5.5/-3.8 mmHg) versus the amlodipine group (-0.1/+0.8 mm Hg). In normotensive children a small decrease in blood pressure was observed in the losartan group (-3.7/-3.4 mm Hg) compared to placebo. No significant correlation between the decline in proteinuria and blood pressure was noted, however it is possible that the decline in blood pressure was responsible, in part, for the decline in proteinuria in the losartan treated group. Long-term effects of losartan in children with proteinuria were studied for up to 3 years in the open-label safety extension phase of the same study, in which all patients completing the 12-week base study were invited to participate. A total of 268 patients entered the open-label extension phase and were re-randomized to losartan (N=134) or enalapril (N=134) and 109 patients had &ge;3 years of follow-up (pre-specified termination point of &ge;100 patients completing 3 years of follow-up in the extension period). The dose ranges of losartan and enalapril, given according to investigator discretion, were 0.30 to 4.42 mg/kg/day and 0.02 to 1.13 mg/kg/day, respectively. The maximum daily doses of 50 mg for 50 kg were not exceeded for most patients during the extension phase of the study. In summary, the results of the safety extension show that losartan was well-tolerated and led to sustained decreases in proteinuria with no appreciable change in glomerular filtration rate (GFR) over 3 years. For normotensive patients (n=205), enalapril had a numerically greater effect compared to losartan on proteinuria (-33.0% (95%CI -47.2;- 15.0) vs -16.6% (95%CI -34.9; 6.8)) and on GFR ( 9.4(95%CI 0.4; 18.4) vs -4.0(95%CI - 13.1; 5.0) ml/min/1.73m2)). For hypertensive patients (n=49), losartan had a numerically greater effect on proteinuria (-44.5% (95%CI -64.8; -12.4) vs -39.5% (95%CI -62.5; - 2.2)) and GFR (18.9(95%CI 5.2; 32.5) vs -13.4(95%CI -27.3; 0.6)) ml/min/1.73m2. An open label, dose-ranging clinical trial was conducted to study the safety and efficacy of losartan in paediatric patients aged 6 months to 6 years with hypertension. A total of 101 patients were randomized to one of three different starting doses of open-label losartan: a low dose of 0.1 mg/kg/day (N=33), a medium dose of 0.3 mg/kg/day (N=34), or a high dose of 0.7 mg/kg/day (N=34). Of these, 27 were infants which were defined as children aged 6 months to 23 months. Study medication was titrated to the next dose level at Weeks 3, 6, and 9 for patients that were not at blood pressure goal and not yet on the maximal dose (1.4 mg/kg/day, not to exceed 100 mg/day) of losartan. Of the 99 patients treated with study medication, 90 (90.9%) patients continued to the extension study with follow up visits every 3 months. The mean duration of therapy was 264 days. In summary, the mean blood pressure decrease from baseline was similar across all treatment groups (change from baseline to Week 3 in SBP was -7.3, -7.6, and -6.7 mmHg for the low-, medium-, and high-dose groups, respectively; the reduction from baseline to Week 3 in DBP was -8.2, -5.1, and -6.7 mmHg for the low-, medium-, and high-dose groups.); however, there was no statistically significant dose-dependent response effect for SBP and DBP. Losartan, at doses as high as 1.4 mg/kg, was generally well tolerated in hypertensive children aged 6 months to 6 years after 12 weeks of treatment. The overall safety profile appeared comparable between treatment groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites. The systemic bioavailability of losartan tablets is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. Distribution Both losartan and its active metabolite are &ge;99% bound to plasma proteins, primarily albumin. The volume of distribution of losartan is 34 litres. Biotransformation About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite. Following oral and intravenous administration of 14C-labelled losartan potassium, circulating plasma radioactivity primarily is attributed to losartan and its active metabolite. Minimal conversion of losartan to its active metabolite was seen in about 1% of individuals studied. In addition to the active metabolite, inactive metabolites are formed. Elimination Plasma clearance of losartan and its active metabolite is about 600 ml/min and 50 ml/min, respectively. Renal clearance of losartan and its active metabolite is about 74 ml/min and 26 ml/min, respectively. When losartan is administered orally, about 4% of the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the urine as active metabolite. The pharmacokinetics of losartan and its active metabolite are linear with oral losartan potassium doses up to 200 mg. Following oral administration, plasma concentrations of losartan and its active metabolite decline polyexponentially, with a terminal half-life of about 2 hours and 6-9 hours, respectively. During once-daily dosing with 100 mg, neither losartan nor its active metabolite accumulates significantly in plasma. Both biliary and urinary excretions contribute to the elimination of losartan and its metabolites. Following an oral dose/intravenous administration of 14C-labelled losartan in man, about 35% / 43% of radioactivity is recovered in the urine and 58%/ 50% in the faeces. Characteristics in patients In elderly hypertensive patients the plasma concentrations of losartan and its active metabolite do not differ essentially from those found in young hypertensive patients. In female hypertensive patients the plasma levels of losartan were up to twice as high as in male hypertensive patients, while the plasma levels of the active metabolite did not differ between men and women. In patients with mild to moderate alcohol-induced hepatic cirrhosis, the plasma levels of losartan and its active metabolite after oral administration were respectively 5 and 1.7 times higher than in young male volunteers (see section 4.2 and 4.4). Plasma concentrations of losartan are not altered in patients with a creatinine clearance above 10 ml/minute. Compared to patients with normal renal function, the AUC for losartan is about 2-times higher in haemodialysis patients. The plasma concentrations of the active metabolite are not altered in patients with renal impairment or in haemodialysis patients. Neither losartan nor the active metabolite can be removed by haemodialysis. Pharmacokinetics in paediatric patients The pharmacokinetics of losartan have been investigated in 50 hypertensive paediatric patients &gt; 1 month to &lt; 16 years of age following once daily oral administration of approximately 0.54 to 0.77 mg/ kg of losartan (mean doses). The results showed that the active metabolite is formed from losartan in all age groups. The results showed roughly similar pharmacokinetic parameters of losartan following oral administration in infants and toddlers, preschool children, school age children and adolescents. The pharmacokinetic parameters for the metabolite differed to a greater extent between the age groups. When comparing preschool children with adolescents these differences became statistically significant. Exposure in infants/ toddlers was comparatively high.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, genotoxicity and carcinogenic potential. In repeated dose toxicity studies, the administration of losartan induced a decrease in the red blood cell parameters (erythrocytes, haemoglobin, haematocrit), a rise in urea-N in the serum and occasional rises in serum creatinine, a decrease in heart weight (without a histological correlate) and gastro-intestinal changes (mucous membrane lesions, ulcers, erosions, haemorrhages). Like other substances that directly affect the renin-angiotensin system, losartan has been shown to induce adverse reactions on the late foetal development, resulting in foetal death and malformations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Excipients: </strong></p><p>Microcrystalline Cellulose Croscarmellose Sodium Type A Colloidal Silicon Dioxide Purified Talc Magnesium Stearate</p><p><strong>Coating Materials: </strong></p><p>Polysorbate 80 Titanium Dioxide Purified Talc Polyethylene Glycol MW 6000 Hydroxypropyl Methylcellulose Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36Months/3Years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30/pack Reel PVC/PVDC and aluminium foil lid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2017. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>